Patents by Inventor Robert George E. HOLGATE

Robert George E. HOLGATE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ASSESSMENT OF CEACAM1 EXPRESSION ON TUMOR INFILTRATING LYMPHOCYTES
    Publication number: 20240092934
    Abstract: Provided are methods and compositions comprising antibodies capable of specific binding to human CEACAM1 molecules, for treating and diagnosing cancer as well as assessing CEACAM1 expression in tumor infiltrating immune cells (TILs) in a biological sample obtained from a [cancer] subject.
    Type: Application
    Filed: November 24, 2023
    Publication date: March 21, 2024
    Applicant: FAMEWAVE LTD.
    Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Rona ORTENBERG, Jacob SCHACHTER, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES
  • Humanized antibodies against CEACAM1
    Patent number: 11866509
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: January 9, 2024
    Assignee: FAMEWAVE LTD.
    Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Gal Markel, Jacob Schachter, Rona Ortenberg, Francis Joseph Carr, Robert George E. Holgate, Timothy David Jones
  • Polynucleotides encoding humanized antibodies against CEACAM1
    Patent number: 11427647
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: August 30, 2022
    Assignee: FAMEWAVE LTD.
    Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Gal Markel, Jacob Schachter, Rona Ortenberg, Francis Joseph Carr, Robert George E. Holgate, Timothy David Jones
  • Humanized affinity matured anti-FcRn antibodies
    Patent number: 10822417
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to human serum albumin. The FcRn-binding proteins can be used to treat a variety of disorders including acute and chronic toxic exposure.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: November 3, 2020
    Assignee: Syntimmune, Inc.
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan D. Jones, Derry Roopenian, Robert George E. Holgate, Timothy D. Jones, Arron R. Hearn
  • HUMANIZED ANTIBODIES AGAINST CEACAM1
    Publication number: 20200277398
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Application
    Filed: May 18, 2020
    Publication date: September 3, 2020
    Applicant: Famewave Ltd.
    Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Jacob SCHACHTER, Rona ORTENBERG, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES
  • HUMANIZED ANTIBODIES AGAINST CEACAM1
    Publication number: 20200216557
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Application
    Filed: December 2, 2019
    Publication date: July 9, 2020
    Applicant: Famewave Ltd.
    Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Jacob SCHACHTER, Rona ORTENBERG, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES
  • Humanized antibodies against CEACAM1
    Patent number: 10550196
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: February 4, 2020
    Assignee: Famewave Ltd.
    Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Gal Markel, Jacob Schachter, Rona Ortenberg, Francis Joseph Carr, Robert George E. Holgate, Timothy David Jones
  • HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES
    Publication number: 20190135915
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to human serum albumin. The FcRn-binding proteins can be used to treat a variety of disorders including acute and chronic toxic exposure.
    Type: Application
    Filed: April 25, 2017
    Publication date: May 9, 2019
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan D. Jones, Derry Roopenian, Robert George E. Holgate, Timothy D. Jones, Arron R. Hearn
  • HUMANIZED ANTIBODIES AGAINST CEACAM1
    Publication number: 20170044270
    Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
    Type: Application
    Filed: April 27, 2015
    Publication date: February 16, 2017
    Applicant: CCAM BIOTHERAPEUTICS LTD.
    Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Jacob SCHACHTER, Rona ORTENBERG, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES